Industry Trend

Site Sections


Menu













© 2023. All Rights reserved.

Overview for CHUGAI PHARMACEUTICAL

All Data per May 25, 2023

Industry:

Drug Manufacturers—General

Last Close:

3,753.00 JPY

Expected Dividend:

2.08 %

Payoffs per Year:

2
Business Summary

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.


Competitors View

Ordering

PFIZER

USA
0.89 3.74%
4.36%
6.07% 4.49% 1.0 0.61
-43.29%
46.05 16.02% 48.64 1.0

ABBVIE

USA
1.02 3.5%
4.3%
10.17% 5.07% 1.0 3.15
-14.88%
42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR
1.06 3.6%
2.11%
5.97% 4.3% 0.5 16.21
-3.86%
67.14 17.71% 38.41 3.0

SANOFI

FRA
1.11 3.8%
3.58%
1.59% 3.73% 1.0 0.88
-12.18%
49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN
0.98 1.38%
2.08%
16.13% 2.65% 1.0 3.06
-38.8%
42.96 15.38% 77.21 5.0

MERCK & CO.

USA
1.09 3.4%
2.67%
5.29% 3.94% 1.0 3.67
-11.68%
47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA
0.95 2.6%
4.47%
2.48% 2.66% 1.0 0.53
-24.44%
34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN
1.01 2.35%
2.85%
19.78% 5.38% 1.0 1.47
-19.06%
31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA
1.1 2.36%
1.06%
14.8% 4.25% 1.0 11.83
-12.71%
45.05 7.83% 21.77 9.0

AMGEN

USA
0.95 2.75%
3.93%
10.11% 3.97% 1.0 1.83
-17.4%
38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN
1.07 2.05%
0.7%
6.06% 2.46% 1.0 10.21
-17.26%
41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN
0.95 1.65%
1.91%
8.0% 2.16% 1.0 3.07
-15.61%
44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN
1.01 2.16%
1.93%
0.0% 1.98% 1.0 0.44
-14.62%
29.23 12.66% 72.92 13.0

ROCHE

CHE
0.92 3.1%
3.27%
1.69% 3.06% 1.0 0.55
-23.37%
40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA
1.04 3.5%
3.89%
3.61% 3.76% 0.5 0.24
-42.43%
36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA
0.96 2.69%
3.05%
5.9% 3.2% 1.0 0.19
-12.62%
46.37 -0.95% 40.99 16.0

BAYER

GER
1.06 2.96%
3.68%
0.81% 2.81% 0.5 -0.3
-58.76%
37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR
1.02 6.49%
2.62%
0.0% 5.95% -1.0 0.02
-24.56%
47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP
0.91 1.1%
0.0%
-53.18% 0.2% -0.5 -0.11
-65.73%
32.66 2.01% 38.04 19.0


Information for CHUGAI PHARMACEUTICAL

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 78.00 3,753.00 2.08
2022 78.00 3,368.00 2.32
2021 76.00 3,735.00 2.03
2020 100.00 5,503.00 1.82
2019 32.00 3,360.00 0.95
2018 24.00 2,126.67 1.13
2017 20.67 1,923.33 1.07
2016 17.33 1,118.33 1.55
2015 19.33 1,413.33 1.37
2014 16.00 988.00 1.62
2013 15.00 775.00 1.94

Fundamentals

Chart